The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion
Introduction
The intravenous (i.v.) administration of the β-blocker metoprolol during ongoing ischemia has been shown to increase myocardial salvage [1]. However, the mechanisms responsible for the observed cardioprotection remain elusive. Clinical guidelines recommend the oral administration of β-blockers in patients with acute myocardial infarction (MI) [2]; though, whether the oral administration of metoprolol, initiated early after coronary reperfusion, as current clinical practice guidelines recommend [2], exerts similar effect on myocardial salvage is also unknown.
Indirect evidence suggest that the early i.v. initiation of β-blockers before mechanical reperfusion result in less cardiovascular events and improved myocardial recovery [3], however a study systematically comparing the pre-reperfusion β-blocker administration vs. the oral post-reperfusion route of administration is lacking. The understanding of the impact of the time of β-blocker initiation may have clinical implications, since the early i.v. route of β-blocker initiation is not encouraged [2], [4].
Recent literature supports the notion that metoprolol can block the migration of neutrophils both in vitro [5] and in vivo [6], and also display antiapoptotic properties in different conditions like heart failure [7]. Both mechanisms (neutrophil infiltration and apoptosis) have been proposed as major contributors to reperfusion injury [8], [9]. Therefore, we hypothesized that the cardioprotective effect of metoprolol could be mediated via reduction in reperfusion injury, and therefore restricted to its administration before the restoration of coronary flow.
The aims of the present work were to compare the extent of myocardial salvage associated with the pre-reperfusion i.v. administration of metoprolol in comparison with its oral post-reperfusion initiation. We additionally studied the effect of metoprolol administration on suspected markers of myocardial reperfusion injury.
Section snippets
Study design
A reperfused anterior MI was induced in thirty male Yorkshire Albino pigs (weight 28 ± 0.5 kg). Animals were randomized 1:1:1 to 1) i.v. metoprolol before reperfusion followed by oral metoprolol after reperfusion (pre-reperfusion-metoprolol group), 2) i.v. placebo before reperfusion followed by oral metoprolol after reperfusion (post-reperfusion-metoprolol group) or 3) i.v. placebo before reperfusion alone (placebo group). Eighteen animals underwent cardiac magnetic resonance imaging (MRI) 72 h
Results
All three groups showed a similar mean heart rate during the procedure (66 ± 2, 69 ± 3 and 66 ± 3 bpm for the pre-reperfusion-, post-reperfusion-metoprolol and placebo groups, respectively; P = NS).
Discussion
Myocardial infarct size has been shown to be a strong predictor of cardiovascular events [16]. Beyond early reperfusion (the major determinant of cardioprotection [17]), therapies that can reduce the size of MI are strongly needed [18].
β-blockers are of clinical value in the setting of acute MI, with a large body of evidence showing mortality reductions when administered early [19]. The use of oral β-blockade constitutes a class I indication in clinical practice guidelines [20]; however, its
Conclusions
In an animal model of acute myocardial infarction, we have studied the effect of metoprolol on myocardial infarct size and on suspected markers of reperfusion injury. Here we show that the cardioprotective effect of metoprolol, as evaluated 3 days post-AMI, is restricted to its administration prior to reperfusion (during ongoing ischemia). The cardioprotection granted by the intravenous pre-reperfusion-metoprolol administration was associated with a significant reduction in myocardial apoptosis
Acknowledgements
BI was granted by the Working Group on Ischemic Heart Disease of the Spanish Society of Cardiology, SP by a Fellowship of Fundación CajaMadrid, and GV is a Juan de la Cierva investigator of MEC. GV and LB are members of CIBEROBN-Institute Carlos III and are funded by PNS 2006-10091 from MEC, Spain.
The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology [30].
References (30)
- et al.
Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction
J Am Coll Cardiol
(2004) - et al.
Modulation of neutrophil migration and superoxide anion release by metoprolol
J Mol Cell Cardiol
(2000) - et al.
Metoprolol treatment decreases tissue myeloperoxidase activity after spinal cord injury in rats
J Clin Neurosci
(2007) - et al.
Beta-adrenergic receptor blockade modulates Bcl-X(S) expression and reduces apoptosis in failing myocardium
J Mol Cell Cardiol
(2003) - et al.
Rapid change in plaque size, composition and molecular footprint following recombinant ApoA-IMilano (ETC-216) administration. Magnetic resonance imaging study in an experimental model of atherosclerosis
J Am Coll Cardiol
(2008) - et al.
Cardiac protection during acute myocardial infarction: where do we stand in 2004?
J Am Coll Cardiol
(2004) - et al.
Impact of organizational infrastructure on beta-blocker and aspirin therapy for acute myocardial infarction
Am Heart J
(2006) - et al.
Animal models of cardiovascular disease
Rev Esp Cardiol
(2009) Ethical authorship and publishing
Int J Cardiol
(2009)- et al.
Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance
Circulation
(2007)